Brown Advisory Inc. Has $120.30 Million Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Brown Advisory Inc. decreased its position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 12.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,814,403 shares of the company's stock after selling 255,598 shares during the period. Brown Advisory Inc. owned about 2.11% of HealthEquity worth $120,295,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in HealthEquity by 19.1% in the 3rd quarter. FMR LLC now owns 5,648,992 shares of the company's stock valued at $412,659,000 after buying an additional 907,743 shares during the period. Mackenzie Financial Corp raised its stake in shares of HealthEquity by 58.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company's stock worth $119,831,000 after purchasing an additional 664,979 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of HealthEquity by 164.6% during the 3rd quarter. Invesco Ltd. now owns 484,043 shares of the company's stock valued at $35,359,000 after buying an additional 301,078 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of HealthEquity by 12.1% in the 3rd quarter. Clearbridge Investments LLC now owns 2,204,675 shares of the company's stock valued at $161,051,000 after buying an additional 238,116 shares in the last quarter. Finally, Eagle Asset Management Inc. acquired a new position in HealthEquity in the third quarter worth approximately $15,581,000. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HQY has been the subject of several analyst reports. JMP Securities started coverage on HealthEquity in a report on Thursday, April 4th. They issued a "mkt outperform" rating and a $101.00 target price for the company. KeyCorp raised their target price on shares of HealthEquity from $85.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, March 22nd. JPMorgan Chase & Co. boosted their target price on shares of HealthEquity from $86.00 to $108.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 2nd. Barrington Research reaffirmed an "outperform" rating and issued a $100.00 price target on shares of HealthEquity in a research report on Friday, March 22nd. Finally, BTIG Research boosted their price objective on HealthEquity from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, March 20th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.17.

HealthEquity Trading Up 1.0 %

NASDAQ:HQY traded up $0.81 on Friday, hitting $79.21. 391,617 shares of the stock were exchanged, compared to its average volume of 560,201. The stock has a market capitalization of $6.80 billion, a price-to-earnings ratio of 123.77, a P/E/G ratio of 1.28 and a beta of 0.55. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.76 and a current ratio of 4.76. HealthEquity, Inc. has a 52 week low of $54.09 and a 52 week high of $84.49. The company's 50-day moving average price is $80.03 and its 200 day moving average price is $75.02.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.08. The company had revenue of $262.39 million during the quarter, compared to analyst estimates of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. On average, equities research analysts forecast that HealthEquity, Inc. will post 2.12 earnings per share for the current year.

Insider Activity at HealthEquity

In other HealthEquity news, CEO Jon Kessler sold 33,765 shares of the stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the completion of the transaction, the chief executive officer now owns 126,635 shares in the company, valued at approximately $10,106,739.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Delano Ladd sold 2,558 shares of the firm's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $82.59, for a total value of $211,265.22. Following the completion of the transaction, the executive vice president now owns 47,438 shares of the company's stock, valued at $3,917,904.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the transaction, the chief executive officer now owns 126,635 shares of the company's stock, valued at $10,106,739.35. The disclosure for this sale can be found here. In the last three months, insiders sold 68,823 shares of company stock worth $5,482,975. 2.70% of the stock is owned by company insiders.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.